FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:560-563 February 6, 2003 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PDF of corrected article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Wood, A. J.J. Related Article by Gaspoz, J.-M. Related Article by Gaspoz, J.-M. PubMed Citation

To the Editor: Gaspoz et al. (June 6 issue)¹ present an interesting perspective on the problem of escalating health care costs. Their comparison between the cost effectiveness of aspirin and that of clopidogrel is commendable, given the increasing focus by the public on the costs of newer drugs. In their analysis, the authors' assumptions about the costs of the drugs do not take into consideration future costs that would be expected to be lower for both brand-name and generic versions of clopidogrel.

Estimates of the cost of developing a new drug vary, with some figures as high as $800 million.² . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.